Rowan, Courtney M.Paczesny, Sophie2020-06-102020-06-102019-03Rowan, C. M., & Paczesny, S. (2019). Biomarkers for Early Complications After Hematopoietic Stem Cell Transplantation. Clinics in laboratory medicine, 39(1), 61–72. https://doi.org/10.1016/j.cll.2018.10.005https://hdl.handle.net/1805/22928The advancement in technology, particularly in the field of omics, has led to numerous discoveries of biomarkers for early post-HSCT complications. Future research must include the testing of newly discovered biomarkers against existing, validated biomarkers. Work also needs to be done to implement the promising, validated biomarkers into clinical practice in a time-efficient and cost-effective manner. The prognostic biomarkers should be incorporated into clinical trials so that the effect of early recognition on the outcomes of HSCT recipients can be assessed. Diagnostic biomarkers can help to differentiate the complex variety of diseases that can be present in this population. Finally, biomarkers that can serve as therapeutic targets should be further studied. Many of these post-HSCT complications have limited or nonspecific therapeutic options. For example, corticosteroids are the first-line therapy for aGVHD. Using biomarkers to help identify underlying biologic pathways may open new therapeutic avenues that deserve investigation. This major advancement in technology allows for early diagnosis of complications, risk stratification for complications, and potential new therapeutic targets. All of these strides can improve the utilization of life-saving allogeneic HSCT while minimizing complications and mortality.en-USPublisher PolicyBiomarkersHematopoietic stem cell transplantationProteomicsGraft versus host diseaseArticle